Atlas Trials

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Clinical trial NCT04961996 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04961996
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Early Breast Cancer
Start date
2021-08-27
Primary completion
2025-08-08
Enrollment
4170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.